The Latest Breaking News from MedSurg

Despite Stryker’s underperformance relative to its peers over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Although Solventum has outperformed the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Summary Stryker Corporation (SYK) shows strong technical buy signals, with a 6.09% gain since 8/21, and consistent price appreciation across key moving averages. The company operates in MedSurg, Neurotechnology, Orthopaedics, and Spine segments, offering a wide range of medical devices and technologies. Analysts provide mixed ratings, with price targets ranging...

Boston Scientific has significantly outperformed the broader market YTD, and Wall Street analysts are still bullish about the stock’s prospects.

Weakness in the S&P 500 has made life unpleasant for investors so far in 2022, but it has also created buying opportunities in a handful of high-quality stocks. Long-term investors looking to buy the dip can find plenty of stocks to buy that are at or near their lowest prices…

Boston Scientific Corp (NYSE:BSX) generated net sales of $3.026 billion in Q1 FY22, beating the Wall Street estimate of $2.95 billion. Sales increased 10% Y/Y on a reported basis, 12.6% on an operational basis, and 9.7% on an organic basis, better than the management estimate of approximately 5% - 8%. The Company achieved…